Inhaled Nitric Oxide Market Size 2024-2028
The inhaled nitric oxide market size is forecast to increase by USD 462.5 million at a CAGR of 10.77% between 2023 and 2028.
- Inhaled nitric oxide (iNO) is a gaseous drug that has gained significant attention In the healthcare industry due to its therapeutic benefits. The market for iNO is driven by several factors, including its increasing use in cardiac surgeries to improve cardiac output and reduce the risk of complications. Furthermore, the rising number of patients suffering from chronic obstructive pulmonary disease (COPD) is expected to fuel market growth, as iNO is an effective bronchodilator for COPD patients. However, the market also faces challenges, such as the potential adverse effects of iNO, including methemoglobinemia and increased risk of infection. Proper monitoring and administration techniques can mitigate these risks, ensuring the safe and effective use of iNO in clinical settings.Overall, the iNO market is poised for growth, driven by its therapeutic benefits and the increasing prevalence of conditions that can be treated with this drug.
What will be the Size of the Inhaled Nitric Oxide Market During the Forecast Period?
- The market encompasses the production and supply of nitric oxide (NO) for therapeutic applications, particularly In the treatment of various respiratory disorders. NO, a colorless, odorless gas, possesses potent vasodilatory properties, making it an essential pulmonary vasodilator for managing conditions like respiratory distress syndrome (RDS), pulmonary hypertension, and persistent pulmonic hypertension of the newborn. It is also used to improve oxygenation in cases of ventilation-perfusion mismatch. NO's antimicrobial properties contribute to its application in treating respiratory infections. Beyond the neonatal population, NO finds use in managing respiratory complications In the geriatric population and certain respiratory disorders like asthma. In addition, NO is explored for its potential benefits in enhancing athletic performance, with some researchers investigating its use as an alternative to nitrogen, argon, hydrogen, and carbon monoxide for athletes and fitness enthusiasts.
How is this Inhaled Nitric Oxide Industry segmented and which is the largest segment?
The inhaled nitric oxide industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
- Application
- Neonatal respiratory treatment
- Chronic obstructive pulmonary disease (COPD)
- Acute respiratory distress syndrome (ARDS)
- Others
- Geography
- North America
- US
- APAC
- China
- India
- Europe
- Germany
- UK
- South America
- Middle East and Africa
- North America
By Application Insights
- The neonatal respiratory treatment segment is estimated to witness significant growth during the forecast period.
The market is primarily driven by the neonatal respiratory treatment segment. The rise in neonatal respiratory disorders, including persistent pulmonary hypertension and hypoxic respiratory failure, necessitates the use of inhaled nitric oxide for improved oxygenation. Inhaled nitric oxide, a selective pulmonary vasodilator, is an effective treatment for preterm infants with hypoxemic respiratory failure caused by neonatal pulmonary hypertension. Neonatal hypoxic respiratory failure is a significant concern due to complications such as ventilation-perfusion mismatch and pulmonary vascular resistance, leading to hypertension and oxygenation issues. Inhaled nitric oxide's vasodilatory and anti-inflammatory properties make it a valuable therapeutic option for various respiratory and cardiovascular disorders, including respiratory distress syndrome, pulmonary hypertension, and cardio-cerebrovascular disorders.
The geriatric population and individuals with asthma, coronavirus disease, and coronavirus strains also benefit from this medical technology. Despite regulatory guidelines and pricing and reimbursement challenges, the pharmaceuticals industry continues to invest In the development of advanced delivery systems and administration techniques for inhaled nitric oxide. Inhaled nitric oxide is available as a gas, typically mixed with other gases like nitrogen, argon, hydrogen, carbon monoxide, or oxygen. The market for inhaled nitric oxide is expected to grow due to its potential applications in various healthcare conditions and the increasing awareness of its benefits.
Get a glance at the Inhaled Nitric Oxide Industry report of share of various segments Request Free Sample
The Neonatal respiratory treatment segment was valued at USD 216.80 million in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
- North America is estimated to contribute 30% to the growth of the global market during the forecast period.
Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
The market in North America is significantly large due to the presence of major market participants, a well-established healthcare sector, and increasing prevalence of respiratory disorders. The US and Canada, in particular, contribute significantly to market growth due to substantial healthcare investments. According to the Centers for Medicare and Medicaid Services (CMS), US healthcare spending is projected to increase by an average of 5.5% annually from 2018-2027, reaching nearly USD6.0 trillion by 2027. This growth in healthcare expenditure enhances access to advanced therapies, driving market expansion. Inhaled Nitric Oxide is a pulmonary vasodilator and has anti-inflammatory properties, making it beneficial for various respiratory disorders, including preterm birth, respiratory distress syndrome, and hypoxic respiratory failure.
It also aids in addressing pulmonary hypertension, hypoxemia, and ventilation-perfusion mismatch. The geriatric population and those suffering from cardio-cerebrovascular disorders, asthma, and coronavirus diseases can also benefit from this therapeutic gas. The Pharmaceuticals industry focuses on developing delivery systems and administration techniques to improve patient outcomes, adhering to regulatory guidelines. The market faces pricing and reimbursement challenges, which may impact growth. Key players include Nitric Oxide, Nitrogen, Argon, Hydrogen, Carbon Monoxide, and Oxygen.
Market Dynamics
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise In the adoption of Inhaled Nitric Oxide Industry?
Use of inhaled nitric oxide in cardiac surgeries is the key driver of the market.
- Inhaled nitric oxide is a vital gas with essential roles in human physiology, including inflammation reduction and neuronal transmission. Its therapeutic applications have expanded, particularly in treating hypoxemic respiratory failure and right ventricular dysfunction during cardiac surgery. Inhaled nitric oxide acts as a selective pulmonary vasodilator, improving oxygenation by reducing pulmonary vascular resistance and pulmonary hypertension. This gas quickly binds to hemoglobin, maintaining systemic blood pressure and mitigating surgical complications. Respiratory disorders, such as preterm birth-related complications, respiratory distress syndrome, and hypoxic respiratory failure, are significant indications for inhaled nitric oxide therapy. Additionally, it has shown promise in treating cardiovascular disorders, including pulmonary hypertension and cardio-cerebrovascular disorders.
- Nitric oxide's anti-inflammatory properties contribute to its use in various respiratory diseases. Healthcare providers increasingly recognize the benefits of inhaled nitric oxide therapy, but regulatory hurdles and financial burdens pose challenges to its widespread adoption. The medical technology industry continues to innovate, developing advanced delivery systems and administration techniques to improve patient outcomes and reduce costs. Inhaled nitric oxide is administered as a gas, often in combination with other gases like nitrogen, argon, hydrogen, or oxygen. The pharmaceuticals industry invests in research and development to explore nitric oxide's antimicrobial properties and potential applications in treating coronavirus diseases and other cardio-respiratory conditions.
- The geriatric population and individuals with asthma may also benefit from inhaled nitric oxide therapy. However, the use of this gas is not limited to medical applications; athletes and fitness enthusiasts employ it to enhance performance. In conclusion, inhaled nitric oxide therapy offers significant benefits in treating various respiratory and cardiovascular disorders. Its use as a selective pulmonary vasodilator and anti-inflammatory agent makes it a valuable addition to healthcare providers' arsenal. Despite regulatory challenges and financial burdens, the medical technology industry continues to innovate, ensuring that this essential gas remains accessible to those who need it most.
What are the market trends shaping the Inhaled Nitric Oxide Industry?
Rise In the number of patients with COPD is the upcoming market trend.
- Inhaled nitric oxide (iNO) is a vasodilator and pulmonary vasodilator used In the treatment of various respiratory and cardiovascular disorders. Its primary applications include the management of respiratory complications in preterm births, neonates with respiratory distress syndrome, and hypoxic or hypoxemic respiratory failure. INO's anti-inflammatory properties make it beneficial in addressing pulmonary hypertension, ventilation-perfusion mismatch, and pulmonary vascular resistance. The healthcare industry has seen significant growth In the use of iNO due to its therapeutic benefits. However, financial burden and regulatory hurdles continue to pose challenges for its widespread adoption. INO is administered through various delivery systems, including gas segments such as nitric oxide, argon, hydrogen, and carbon monoxide, and oxygen.
- INO's therapeutic applications extend beyond neonatal care to include the geriatric population, asthma, coronavirus disease, and cardio-cerebrovascular disorders. The pharmaceuticals industry is continually researching and developing new administration techniques and regulatory guidelines to improve iNO's efficacy and safety. Despite its benefits, iNO's high cost and complex administration techniques have limited its use to specialized healthcare facilities. Extracorporeal membrane oxygenation and persistent pulmonary hypertension are other areas where iNO holds potential. INO's therapeutic properties make it a valuable tool in addressing various respiratory and cardiovascular disorders. However, its high cost and complex administration techniques necessitate continued research and development efforts to make it more accessible and affordable for patients.
What challenges does the Inhaled Nitric Oxide Industry face during its growth?
Adverse effects of inhaled nitric oxide is a key challenge affecting the industry growth.
- Inhaled nitric oxide is a vasodilator and pulmonary vasodilator used In the treatment of various respiratory and cardiovascular disorders. Its primary indications include preterm birth-related respiratory complications such as respiratory distress syndrome (RDS) and hypoxic respiratory failure. Nitric oxide's therapeutic effects are attributed to its vasodilatory properties, which help improve oxygenation by reducing pulmonary vascular resistance and pulmonary hypertension. Additionally, nitric oxide possesses anti-inflammatory properties, making it beneficial in managing ventilation-perfusion mismatch and hypoxemic respiratory failure. However, the use of inhaled nitric oxide is not without challenges. The toxicological effects of nitric oxide can be challenging to distinguish from its pharmacological characteristics.
- Nitric oxide can combine with oxygen to form nitrogen dioxide, a strong lung irritant, and interact with superoxide anion to create peroxynitrite, a cytotoxic oxidant. These side effects can impact surfactant performance and contribute to the financial burden of healthcare providers. Regulatory hurdles and pricing and reimbursement challenges further limit the widespread adoption of inhaled nitric oxide. The pharmaceuticals industry is continuously researching and developing new delivery systems and administration techniques to mitigate these challenges and improve patient outcomes. Beyond its use in neonatal care, inhaled nitric oxide has applications in managing respiratory disorders In the geriatric population, cardio-cerebrovascular disorders, and asthma.
- The ongoing coronavirus disease pandemic has also highlighted the potential role of nitric oxide in managing cardiovascular complications associated with different coronavirus strains. The gas segment, which includes nitric oxide, nitrogen, argon, hydrogen, carbon monoxide, and oxygen, is a significant contributor to the medical technology industry. The awareness and understanding of the therapeutic potential of these gases continue to grow, driving innovation and investment In the pharmaceuticals industry.
Exclusive Customer Landscape
The inhaled nitric oxide market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the inhaled nitric oxide market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, inhaled nitric oxide market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.
Air Liquide SA - Inhaled nitric oxide, specifically Kinox, is a selective pulmonary vasodilator designed for neonatal treatment. This therapeutic agent, which does not include specific product descriptions from our company, functions by relaxing the smooth muscles In the lungs' blood vessels, thereby improving oxygenation and blood flow in newborns with respiratory distress. The application of inhaled nitric oxide in neonatal care aims to enhance pulmonary function and support optimal health outcomes for these vulnerable patients.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Air Liquide SA
- Berkeley Life and L2G North America Inc.
- Beyond Air Inc
- Geno Pharmaceuticals Pvt. Ltd.
- Getinge AB
- Halma Plc
- HumanN
- Inspiration Healthcare Group Plc.
- Linde Plc
- Mallinckrodt Plc
- Merck KGaA
- Moda Health Plan Inc.
- NIOX Group plc
- SOL India Pvt Ltd
- The Cigna Group
- Uniscience Group
- VERO Biotech
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Research Analyst Overview
Inhaled nitric oxide (NO) is a gaseous molecule with significant therapeutic potential in various respiratory and cardiovascular disorders. Its vasodilatory properties make it an effective pulmonary vasodilator, particularly in conditions characterized by hypoxic respiratory failure, pulmonary hypertension, and ventilation-perfusion mismatch. The use of inhaled NO in neonatal care has gained prominence due to its role in managing respiratory distress syndrome and hypoxic respiratory failure in preterm births. Its anti-inflammatory properties contribute to its utility in mitigating inflammation In the lungs, thereby improving oxygenation and reducing the financial burden on healthcare providers. Despite its therapeutic benefits, the adoption of inhaled NO in clinical practice is influenced by several factors.
Regulatory hurdles, pricing and reimbursement, and awareness levels among healthcare providers are some of the key challenges impacting the market dynamics. Inhaled NO is not limited to neonatal care and respiratory disorders. Its cardiovascular applications include managing cardio-cerebrovascular disorders, such as hypertension and pulmonary hypertension, as well as hypoxemic respiratory failure in geriatric populations. The medical technology industry has witnessed significant advancements In the delivery systems and administration techniques for inhaled NO. These developments aim to improve patient safety, efficacy, and convenience, thereby expanding the scope of its applications. The pharmaceuticals industry's interest in inhaled NO is driven by its potential in treating a broad range of respiratory and cardiovascular disorders.
The gas segment, which includes nitric oxide, nitrogen, argon, hydrogen, carbon monoxide, and oxygen, is a significant contributor to the market's growth. Inhaled NO's therapeutic applications extend beyond healthcare. Its antimicrobial properties have attracted the attention of athletes and fitness enthusiasts, who use it to enhance performance and promote recovery. The coronavirus disease (COVID-19) pandemic has highlighted the importance of effective respiratory support systems, such as extracorporeal membrane oxygenation (ECMO), which utilize inhaled NO to manage hypoxemic respiratory failure caused by viral strains. In conclusion, the market is driven by its therapeutic potential in managing various respiratory and cardiovascular disorders.
Factors such as regulatory guidelines, pricing and reimbursement, and awareness levels among healthcare providers influence its adoption. The market's growth is fueled by advancements in delivery systems, administration techniques, and the expanding applications of inhaled NO in various industries.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
144 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.77% |
|
Market growth 2024-2028 |
USD 462.5 million |
|
Market structure |
Concentrated |
|
YoY growth 2023-2024(%) |
9.57 |
|
Key countries |
US, China, India, Germany, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
What are the Key Data Covered in this Inhaled Nitric Oxide Market Research and Growth Report?
- CAGR of the Inhaled Nitric Oxide industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, APAC, Europe, South America, and Middle East and Africa
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the inhaled nitric oxide market growth of industry companies
We can help! Our analysts can customize this inhaled nitric oxide market research report to meet your requirements.